دورية أكاديمية
أعرض في EDS

PRRT with Lu-177 DOTATATE in Treatment-Refractory Progressive Meningioma: Initial Experience from a Tertiary-Care Neuro-Oncology Center.

التفاصيل البيبلوغرافية
العنوان: PRRT with Lu-177 DOTATATE in Treatment-Refractory Progressive Meningioma: Initial Experience from a Tertiary-Care Neuro-Oncology Center.
المؤلفون: Puranik AD; Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Dev ID; Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Rangarajan V; Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Kulkarni S; Department of Radiodiagnosis, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Shetty N; Department of Radiodiagnosis, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Gala K; Department of Radiodiagnosis, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Sahu A; Department of Radiodiagnosis, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Bhattacharya K; Department of Radiodiagnosis, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Dasgupta A; Department of Radiation Oncology, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Chatterjee A; Department of Radiation Oncology, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Gupta T; Department of Radiation Oncology, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Sridhar E; Department of Pathology, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Sahay A; Department of Pathology, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Shetty P; Department of Neurosurgery, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Singh V; Department of Neurosurgery, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Moiyadi A; Department of Neurosurgery, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Menon N; Department of Medical Oncology, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Purandare NC; Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Agrawal A; Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Shah S; Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Choudhury S; Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Ghosh S; Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India., Jha AK; Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
المصدر: Neurology India [Neurol India] 2024 Mar 01; Vol. 72 (2), pp. 278-284. Date of Electronic Publication: 2024 Apr 30.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Medknow Publications Country of Publication: India NLM ID: 0042005 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1998-4022 (Electronic) Linking ISSN: 00283886 NLM ISO Abbreviation: Neurol India Subsets: MEDLINE
أسماء مطبوعة: Publication: Mumbai : Medknow Publications
Original Publication: Bombay : Neurological Society of India
مواضيع طبية MeSH: Octreotide*/*analogs & derivatives, Meningioma*/radiotherapy , Meningioma*/diagnostic imaging , Meningeal Neoplasms*/radiotherapy , Meningeal Neoplasms*/diagnostic imaging , Octreotide*/therapeutic use , Octreotide*/administration & dosage, Humans ; Female ; Male ; Middle Aged ; Adult ; Organometallic Compounds/therapeutic use ; Aged ; Treatment Outcome ; Radiopharmaceuticals/therapeutic use ; Receptors, Peptide ; Tertiary Care Centers ; Disease Progression
مستخلص: Purpose: Refractory and/or recurrent meningiomas have poor outcomes, and the treatment options are limited. Peptide receptor radionuclide therapy (PRRT) has been used in this setting with promising results. We have documented our experience of using intravenous (IV) and intra-arterial (IA) approaches of Lu-177 DOTATATE PRRT.
Methods: Eight patients with relapsed/refractory high-grade meningioma received PRRT with Lu-177 DOTATATE by IV and an IA route. At least 2 cycles were administered. Time to progression was calculated from the first PRRT session to progression. The response was assessed on MRI using RANO criteria, and visual analysis of uptake was done on Ga-68 DOTANOC PET/CT. Post-therapy dosimetry calculations for estimating the absorbed dose were performed.
Results: Median time to progression was 8.9 months. One patient showed disease progression, whereas seven patients showed stable disease at 4 weeks following 2 cycles of PRRT. Dosimetric analysis showed higher dose and retention time by IA approach. No significant peri-procedural or PRRT associated toxicity was seen.
Conclusion: PRRT is a safe and effective therapeutic option for relapsed/refractory meningioma. The IA approach yields better dose delivery and should be routinely practised.
(Copyright © 2024 Copyright: © 2024 Neurology India, Neurological Society of India.)
References: Toh CH, Castillo M, Wong AM, Wei KC, Wong HF, Ng SH, et al. Differentiation between classic and atypical meningiomas with use of diffusion tensor imaging. AJNR Am J Neuroradiol 2008;29:1630–5.
Whittle IR, Smith C, Navoo P, Collie D. Meningiomas. Lancet 2004;363:1535–43.
Gritsch S, Batchelor TT, Gonzalez Castro LN. Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. Cancer 2022;128:47–58.
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol 2021;23:1231–51.
Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol 2016;17:e383–91.
Rogers CL, Won M, Vogelbaum MA, Perry A, Ashby LS, Modi JM, et al. High-risk meningioma: Initial outcomes from NRG oncology/RTOG 0539. Int J Radiat Oncol Biol Phys 2020;106:790–9.
Graillon T, Tabouret E, Chinot O. Chemotherapy and targeted therapies for meningiomas: What is the evidence? Curr Opin Neurol 2021;34:857–67.
Wu W, Zhou Y, Wang Y, Liu L, Lou J, Deng Y, et al. Clinical significance of somatostatin receptor (SSTR) 2 in meningioma. Front Oncol 2020;10:1633.
Arena S, Barbieri F, Thellung S, Pirani P, Corsaro A, Villa V, et al. Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neurooncol 2004;66:155–66.
Lawhn-Heath C, Fidelman N, Chee B, Jivan S, Armstrong E, Zhang L, et al. Intraarterial peptide receptor radionuclide therapy using 90Y-DOTATOC for hepatic metastases of neuroendocrine tumors. J Nucl Med 2021;62:221–7.
Purandare NC, Puranik A, Shah S, Agrawal A, Gupta T, Moiyadi A, et al. Differentiating dural metastases from meningioma: Role of 68Ga DOTA-NOC PET/CT. Nucl Med Commun 2020;41:356–62.
Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O’Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013;40:800–16.
Huang RY, Bi WL, Weller M, Kaley T, Blakeley J, Dunn I, et al. Proposed response assessment and endpoints for meningioma clinical trials: Report from the response assessment in NeuroOncology Working Group. Neuro Oncol 2019;21:26–36.
Ahmad H, Schiff D. Multimodality therapy of patients with refractory meningiomas. Curr Treat Options Oncol 2019;20:50.
Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: A RANO review. Neuro Oncol 2014;16:829–30.
Mirian C, Duun-Henriksen AK, Maier A, Pedersen MM, Jensen LR, Bashir A, et al. Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma: Individual patient data meta-analysis. J Nucl Med 2021;62:507–13.
Vonken EPA, Bruijnen RCG, Snijders TJ, Seute T, Lam MGEH, Keizer B, et al. Intraarterial administration boosts 177 Lu-HA-DOTATATE accumulation in salvage meningioma patients. J Nucl Med 2022;63:406–9.
المشرفين على المادة: RWM8CCW8GP (Octreotide)
AE221IM3BB (lutetium Lu 177 dotatate)
0 (Organometallic Compounds)
0 (Radiopharmaceuticals)
0 (Receptors, Peptide)
تواريخ الأحداث: Date Created: 20240501 Date Completed: 20240501 Latest Revision: 20240702
رمز التحديث: 20240702
DOI: 10.4103/NI.Neurol-India-D-23-00252
PMID: 38691470
قاعدة البيانات: MEDLINE
الوصف
تدمد:1998-4022
DOI:10.4103/NI.Neurol-India-D-23-00252